tiprankstipranks
Advertisement
Advertisement

EXEL Stock Latest News

Exelixis Secures Key Patent Victory, Extends Exclusivity
Company AnnouncementsExelixis Secures Key Patent Victory, Extends Exclusivity
4d ago
8K
EXEL
Exelixis says appeals court affirmed ‘key portion’ of 2024 judgment
PremiumThe Fly
Exelixis says appeals court affirmed ‘key portion’ of 2024 judgment
4d ago
EXEL
Trump Trade: U.S. considering new semiconductor tariffs
PremiumThe Fly
Trump Trade: U.S. considering new semiconductor tariffs
8d ago
MU
AMD
White House to announce drug pricing deals with biotechs, Bloomberg reports
PremiumThe Fly
White House to announce drug pricing deals with biotechs, Bloomberg reports
9d ago
ALKS
ALNY
BMO starts Exelixis at Market Perform into patent cliff
PremiumThe Fly
BMO starts Exelixis at Market Perform into patent cliff
17d ago
EXEL
Exelixis initiated with a Market Perform at BMO Capital
PremiumThe FlyExelixis initiated with a Market Perform at BMO Capital
17d ago
EXEL
Exelixis Earnings Call: Cabo Strength, Zanza Awaited
Premium
Company Announcements
Exelixis Earnings Call: Cabo Strength, Zanza Awaited
28d ago
EXEL
Leerink downgrades Exelixis to Market Perform following Q2 results
Premium
The Fly
Leerink downgrades Exelixis to Market Perform following Q2 results
29d ago
EXEL
Exelixis downgraded to Market Perform from Outperform at Leerink
PremiumThe Fly
Exelixis downgraded to Market Perform from Outperform at Leerink
29d ago
EXEL
Exelixis Targets Residual Colorectal Cancer With New Phase 3 Trial
PremiumCompany Announcements
Exelixis Targets Residual Colorectal Cancer With New Phase 3 Trial
29d ago
EXEL
Exelixis price target raised to $51 from $47 at Stifel
PremiumThe Fly
Exelixis price target raised to $51 from $47 at Stifel
29d ago
EXEL
Exelixis price target lowered to $52 from $56 at Truist
PremiumThe Fly
Exelixis price target lowered to $52 from $56 at Truist
29d ago
EXEL
Exelixis: Buy Rating Reaffirmed on Cabozantinib Resilience, Cost Discipline and Zanzalintinib Upside Despite Near-Term NET Guidance Cut
PremiumRatingsExelixis: Buy Rating Reaffirmed on Cabozantinib Resilience, Cost Discipline and Zanzalintinib Upside Despite Near-Term NET Guidance Cut
30d ago
EXEL
Exelixis reports Q2 non-GAAP EPS 91, consensus 86c
Premium
The Fly
Exelixis reports Q2 non-GAAP EPS 91, consensus 86c
1M ago
EXEL
Exelixis lowers FY26 revenue outlook to $2.5B-$2.55B from $2.525B-$2.625B
Premium
The Fly
Exelixis lowers FY26 revenue outlook to $2.5B-$2.55B from $2.525B-$2.625B
1M ago
EXEL
EXEL Earnings this Week: How Will it Perform?
PremiumPre-Earnings
EXEL Earnings this Week: How Will it Perform?
1M ago
EXEL
Exelixis price target raised to $53 from $50 at Morgan Stanley
PremiumThe Fly
Exelixis price target raised to $53 from $50 at Morgan Stanley
1M ago
EXEL
Exelixis price target raised to $49 from $45 at Barclays
PremiumThe Fly
Exelixis price target raised to $49 from $45 at Barclays
2M ago
EXEL
Exelixis price target raised to $49 from $40 at Wells Fargo
PremiumThe Fly
Exelixis price target raised to $49 from $40 at Wells Fargo
2M ago
EXEL
Citizens healthcare analysts hold an analyst/industry conference call
PremiumThe FlyCitizens healthcare analysts hold an analyst/industry conference call
2M ago
CTMX
EXEL
Exelixis price target raised to $56 from $54 at Truist
Premium
The Fly
Exelixis price target raised to $56 from $54 at Truist
2M ago
EXEL
Exelixis price target raised to $46 from $43 at RBC Capital
Premium
The Fly
Exelixis price target raised to $46 from $43 at RBC Capital
2M ago
EXEL

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >